Hims & Hers Begins Selling Eli Lilly Weight Loss Medications
Reading Time: 3 minutes
The FDA recently revoked the company's temporary permission to manufacture similar GLP-1 medications, which was expected to account for a significant portion of the company's revenue. Shares of Hims & Hers (i) soared on Tuesday, closing up 5.25%. The day's rise was driven by the telemedicine company's announcement that it would sell the blockbuster weight loss drug Zepbound through its platform. Back in the Weight Loss Medication Business On April 1, 2025, Hims & Hers announced that it would begin selling branded versions of Eli Lilly's...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
